Résultats de la recherche
10
Tout
Rechercher les filtres
Mot-clé
media release
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
20 mars 2025 19h11 HE
|
Novartis Pharma AG
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Phase III study showed sustained proteinuria reduction at one...
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA
19 mars 2025 09h00 HE
|
Novartis Pharma AG
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA Treatment with investigational OAV101 IT...
Aktionäre von Novartis heissen an der Generalversammlung 2025 alle Anträge des Verwaltungsrats gut
07 mars 2025 09h11 HE
|
Novartis Pharma AG
Die Aktionärinnen und Aktionäre genehmigten die 28. Dividendenerhöhung in Folge. Für 2024 wird die Dividende auf CHF 3.50 (+6,1%) je Aktie erhöht, was einer Rendite von 3,5% entspricht1Die...
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
07 mars 2025 09h11 HE
|
Novartis Pharma AG
Shareholders approved 28th consecutive dividend increase to CHF 3.50 (+6.1%) per share for 2024, representing a 3.5% yield¹ Shareholders elected Giovanni Caforio as new member and Chair of the Board...
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
28 févr. 2025 09h00 HE
|
Novartis Pharma AG
Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx® (secukinumab) treatment in HS to be presentedNew analyses of 52-week data from Phase III...
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
28 févr. 2025 07h39 HE
|
Novartis Pharma AG
If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney disease with no currently approved treatments2-5 ...
Calgary Health Foundation unveils new endoscopy unit thanks to $10M in donations
18 févr. 2025 17h54 HE
|
Calgary Health Foundation
Calgary, Alberta, Canada, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Calgary Health Foundation is proud to announce the opening of Rockyview General Hospital’s expanded endoscopy unit. The new Florence and...
Calgary Health Foundation announces leadership transition
12 févr. 2025 10h05 HE
|
Calgary Health Foundation
Calgary, Alberta, Canada, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Calgary Health Foundation is embarking on an important leadership transition, honouring the contributions of outgoing President & CEO...
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
11 févr. 2025 01h15 HE
|
Novartis Pharma AG
Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in...
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
31 janv. 2025 01h00 HE
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance from...